In further support, no nuclear receptor binding partners were detected by mass spectrometry of either the NHR-49::YFP full-length or 295422 immunoprecipitations (see Supplementary Data 1)
The FDA has emphasized that compounded drugs may carry risks, including variability in potency and purity
Retatrutide, a not endogenously occurring peptide, stimulated the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R) in cell cultures
Age and hormonal status are important determinants
3-month titration protocols starting at Tier 1 Compounded Tirzepatide (injectable) weekly dual GLP-1/GIP injection Compounded Semaglutide (oral drops) daily sublingual format for needle-averse patients Compounded Tirzepatide (oral drops) oral dual-agonist format Microdosing/Longevity Track (no BMI requirement): Microdose tirzepatide and semaglutide options are available for patients who have already lost weight and want to maintain, or who prefer gentler metabolic support without the standard weight-loss dose escalation GLP-1/GIP + B12 longevity microdose a dual-agonist oral product positioned for metabolic health, inflammation reduction, and cellular health rather than rapid weight loss Included with every GLP-1 plan: Every GLP-1 plan includes a prescription for Zofran (ondansetron) to help relieve nausea and support treatment comfort
